100 Agencies: Williams Labadie

Share this article:
Peter Labadie
Peter Labadie

Williams Labadie, a Chicago-based agency owned by Publicis Healthcare Communications Group (PHCG), evolved last year as it reintegrated speaker management business that had been moved to another PHCG agency in 2008.

“It's 30% of our business now,” CEO Peter Labadie says. “It's probably been the biggest area of growth in the last year or so. Reintegrating the speaker group forced us to reposition, and it's been all for the better, but it's one of the biggest challenges. It's easy to reposition clients. It's hard to reposition yourself. We learned a lot in the process.”

The theme of the new positioning is “measurable brand engagement,” emphasizing key overlaps between the speaker management skill set and the more traditional agency skill set—measurability and engagement. The new positioning launched externally this year and coincided with a move to Chicago's historic Merchandise Mart, near other PHCG agencies.

 

About 70% of the agency's work is now digital. A relationship program for APP Pharmaceuticals' anesthetic Naropin (won in 2010) and a digital “Mystery Case” HCP campaign for long-time client Astellas's cardiovascular diagnostic Lexiscan were among last year's digital highlights.

“Clients want to be quick and smart and not spend a lot of money on paper,” Labadie says. “Even bigger clients are going to digital. Anything that has value in digital will take priority.”

The agency made its first foray into dental work last year after landing AOR status for three products from Dentsply/Tulsa Dental Specialties (Ankylos, GuttaCore, and Vortex Blue). Corporate work was won this year. “The work has parallels to both pharma and device business, so we can bring a lot of our background…to bear,” Labadie explains.  

New work from Astellas included AOR for promotional and digital work on Vaprisol (cardiovascular) and project work for its urology speakers program. The agency also won professional promotional business for 1-800-Doctors; rolled over speaker contracting business for AstraZeneca; and bid and won an assignment to revamp PHCG's corporate web site. This year, physician, nurse and nuclear-tech speaker management efforts expanded in support of Lexiscan.

OTC probiotics company Ganeden was lost after it was acquired. Corporate project work with Medicis and work on Botanical Laboratories' Wellesse (OTC supplements) were both moved in-house.  

Labadie reports revenue was up last year, and headcount held at about 55. A few have joined this year, and hiring hasn't been as big of a challenge as anticipated.  “Compared to prior years, there are number of good candidates, and an awful lot of good freelance people out there—especially in digital,” Labadie says.

Finding synergies between the speaker management side of the business and the rest of the business is a priority.

“I'm trying to find bridges between them and determine what strengths we can cross-pollinate,” Labadie explains. “For example, our strength in digital has helped us in doing digital enhancements for speaker presentations. The speaker business is very much compliance driven, so our digital team really supports development of speaker portal customization.”

This year is going well—revenue is up again, and the agency is pitching new speaker business.

“Every year people get a little less freaked about the recession, but I think the need to do more for less will always be there,” Labadie says. “I understand that. Wouldn't we all want that?”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.